AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Leave a Reply

Your email address will not be published. Required fields are marked *